News | August 24, 2009

vProtect Luminal Shield Stent Receives CE Mark

August 24, 2009 – Prescient Medical Inc. said today it received European CE mark clearance to commercialize its vProtect Luminal Shield Stent System.

The device is now approved for use in improving coronary artery luminal diameter in patients with symptomatic ischemic heart disease.
The novel vProtect Luminal Shield has the potential to change the way interventional cardiologists treat arterial plaques. The vProtect Luminal Shield is designed to minimize arterial injury and its consequences, allowing the vessel to regain and maintain healthy physiological function. The device is a low radial force, thin-strut, self-expanding nitinol mesh, or "Shield" that is designed specifically for softer plaques.

The company developed the stent as a prophylactic treatment for vulnerable plaques that are identified in the coronary arteries.

"We are very pleased with the performance of the Shield in our clinical study program," said principal investigator Juan F. Granada, M.D., Medical Director, Skirball Center for Cardiovascular Research, Cardiovascular Research Foundation, New York, NY. "We achieved excellent technical results. In this clinical series there were no periprocedural MACE events and we achieved device delivery success in all the cases. The Shield continues to demonstrate a very favorable efficacy profile in all cases evaluated to date."

The company is the recipient of the 2009 Frost and Sullivan Award for Product Innovation of the Year Award for vProtect Luminal Shield.

For more information: www.prescientmedical.com

Related Content

FDA Approves Six-Month Primary Endpoint for Tack Endovascular System in Below the Knee Disease
News | Stents Peripheral| July 14, 2017
Intact Vascular Inc. announced the U.S. Food and Drug Administration (FDA) approved an Investigational Device Exemption...
Onyx DES 2.0 mm stent meets primary endpoints in small vessels
News | June 12, 2017
June 12, 2017 – The Medtronic Resolute Onyx Drug-Eluting Stent (DES) met its primary endpoint of target lesion failur
First Pennsylvania Patient Treated in LEADERS FREE II Trial of BioFreedom Drug-Coated Stent
News | Stents Drug Eluting| May 12, 2017
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial assessing the safety and...
Resolute Onyx DES, drug eluting stent, medtronic, gains FDA approval
Technology | Stents Drug Eluting| May 01, 2017
May 1, 2017 — The U.S.
Sponsored Content | Videos | Stents Drug Eluting| May 01, 2017
This video, provided by Medtronic, demonstrates the Resolute Onyx coronary stent.
Tryton Medical, Side Branch Stent, first U.S. commercial case, New York-Presbyterian Hospital, Columbia University Medical Center
News | Stents Bifurcation| March 31, 2017
Tryton Medical Inc. recently announced that the first U.S. commercial case using the Tryton Side Branch Stent was...
Sponsored Content | Videos | Stents Bioresorbable| March 30, 2017
Stephen Ellis, M.D., professor of medicine and director of interventional cardiology at Cleveland Clinic, discusses t
Gore Tigris Vascular Stent, Health Canada approval, PAD, peripheral artery disease
News | Stents Peripheral| March 16, 2017
W. L. Gore & Associates Inc. recently announced the Health Canada approval of the Gore Tigris Vascular Stent, a...
Sponsored Content | Videos | Stents Bifurcation| March 06, 2017
This video, provided by Tryton, demonstrates the implantation of the Tryton Side Branch Stent.
Overlay Init